Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fidia Farmaceutici is set to get back the commercialization rights of Hyalgan (sodium hyaluronate) from Sanofi US.
Subscribe to our email newsletter
Hyalgan is an injectable treatment for knee pain associated with osteoarthritis when simple painkillers or exercise and physical therapy are not enough.
Following the transfer of the rights, Fidia will get the right to promote, distribute and sell Hyalgan in the US through its wholly owned subsidiary, Fidia Pharma USA.
Fidia is the owner and manufacturer of Hyalgan.